1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Novo Nordisk’s Concizumab Could Be First In New Class For Hemophilia

TFPI Inhibitors Have 20 Years Of Bad History

 
• By Alaric DeArment

Phase III data for the drug showed strong efficacy among hemophilia A and B patients with inhibitors. The drug’s approval would help drive continued segmentation of the hemophilia market.

Novo Nordisk presented data from its Phase III explorer7 trial of concizumab • Source: Shutterstock

The results of Novo Nordisk A/S’s Phase III explorer7 trial of concizumab in hemophilia A and B with inhibitors are further support for “segmenting” the hemophilia market similarly to diabetes, something the company has discussed for years. That’s on top of the drug expanding Novo’s already considerable hemophilia treatment portfolio as potentially the first anti-tissue factor pathway inhibitor (TFPI) inhibitor to hit the market, a target marked by failure for more than two decades.

The Danish drug maker presented data from the explorer7 trial on 10 July at the International Society of Thrombosis and Haemostasis’ (ISTH) annual meeting in London, showing a significant reduction in treated spontaneous and traumatic bleeds among patients taking the drug by subcutaneous injection once daily, as compared to those receiving no prophylaxis, as well as a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.